Litcius/Paper detail

Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review

Dun‐Chang Mo, Peng‐Hui Luo, Shang‐Xiao Huang, Han‐Lei Wang, Jianfeng Huang

2020International Immunopharmacology57 citationsDOI

Topics & Concepts

LenvatinibPembrolizumabMedicineInternal medicineOncologyRenal cell carcinomaAdverse effectCancerSorafenibHepatocellular carcinomaImmunotherapyCancer Immunotherapy and BiomarkersCancer Research and TreatmentsPeptidase Inhibition and Analysis
Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review | Litcius